Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

NKTR

Nektar Therapeutics

Feb 13 • 04:00PM ET

71.33

+0.33 0.46 %

Healthcare • Biotechnology • USA • NASD

Feb 13, 4:20 PMNektar Therapeutics announces closing of $460 million public offering, including full exercise of underwriters’ option to purchase additional shares

Peers: AMGN BIIB VRTX GILD REGN INCY IONS SRPT EXEL NBIX

| Held by: VTI VXF XPH SCHA PRFZ IHE LFSC VHT ITOT SCHB

Index	-	P/E	-	EPS (ttm)	-7.94	Insider Own	1.46%	Shs Outstand	20.34M	Perf Week	93.78%
Market Cap	1.45B	Forward P/E	-	EPS next Y	-9.87	Insider Trans	-10.01%	Shs Float	20.04M	Perf Month	97.64%
Enterprise Value	1.35B	PEG	-	EPS next Q	-2.42	Inst Own	80.69%	Short Float	16.40%	Perf Quarter	23.69%
Income	-120.74M	P/S	23.18	EPS this Y	-15.44%	Inst Trans	40.80%	Short Ratio	3.21	Perf Half Y	167.25%
Sales	62.60M	P/B	16.48	EPS next Y	1.74%	ROA	-39.63%	Short Interest	3.29M	Perf YTD	68.71%
Book/sh	4.33	P/C	5.37	EPS next 5Y	-9.84%	ROE	-180.24%	52W High	72.31 -1.36%	Perf Year	433.23%
Cash/sh	13.28	P/FCF	-	EPS past 3/5Y	41.29% 25.49%	ROIC	-52.50%	52W Low	0.43 16411.57%	Perf 3Y	54.39%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.15% -3.00%	Gross Margin	85.92%	Volatility	13.34% 8.32%	Perf 5Y	-79.20%
Dividend TTM	-	EV/Sales	21.53	EPS Y/Y TTM	36.87%	Oper. Margin	-217.83%	ATR (14)	4.88	Perf 10Y	-58.79%
Dividend Ex-Date	-	Quick Ratio	4.24	Sales Y/Y TTM	-32.79%	Profit Margin	-192.87%	RSI (14)	81.88	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.24	EPS Q/Q	29.43%	SMA20	66.57%	Beta	-1.11	Target Price	123.43
Payout	-	Debt/Eq	1.96	Sales Q/Q	-51.13%	SMA50	58.36%	Rel Volume	2.15	Prev Close	71.00
Employees	61	LT Debt/Eq	1.70	Earnings	Nov 06 AMC	SMA200	91.05%	Avg Volume	1.02M	Price	71.33
IPO	May 03, 1994	Option/Short	Yes / Yes	EPS/Sales Surpr.	30.35% 17.26%	Trades		Volume	2,203,367	Change	0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-10-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-26-25	Initiated	Citigroup	Buy	$102
Jun-24-25	Reiterated	H.C. Wainwright	Buy	$6.50 → $120
Jun-24-25	Reiterated	BTIG Research	Buy	$60 → $100
Apr-11-25	Upgrade	Jefferies	Hold → Buy	$2
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform	$6
Jan-08-25	Initiated	B. Riley Securities	Buy	$4
Dec-10-24	Initiated	H.C. Wainwright	Buy	$6.50
Nov-04-24	Initiated	Piper Sandler	Overweight	$7
Sep-30-24	Resumed	BTIG Research	Buy	$4
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$2
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3
Mar-15-22	Downgrade	Mizuho	Buy → Neutral	$35 → $8
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform

Show Previous Ratings

Feb-13-26 04:15PM	Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-11-26 10:23PM	Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering (PR Newswire) +18.48% +7.01%
08:08AM	Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock? (Zacks)
07:42AM	Nektars stock rises 51% on Phase II Rezpeg AD maintenance win (Clinical Trials Arena)
07:35AM	Why Is Nektar Therapeutics Stock Gaining Wednesday? (Benzinga)
02:07AM	Loading…
02:07AM	Nektar Therapeutics Touts 52-Week ResPEG Data in Atopic Dermatitis, Eyes Phase 3 Launch in Q2 (MarketBeat)
Feb-10-26 04:07PM	Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. (Investor's Business Daily) +51.07%
04:05PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
11:57AM	Nektar Therapeutics Stock Is Trending Tuesday: What's Going On? (Benzinga)
07:13AM	Nektar, continuing comeback, says eczema drugs effects hold up in follow-up study (BioPharma Dive)
07:00AM	New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing (PR Newswire)
Feb-09-26 04:15PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026 (PR Newswire)
Feb-02-26 10:02PM	Nektar Therapeutics (NKTR): A Bull Case Theory (Insider Monkey)
Jan-30-26 04:10PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.96%
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
08:45AM	Loading…
Jan-07-26 08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-05-26 05:05PM	Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead (Motley Fool)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-21-25 07:31AM	Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) (Insider Monkey)
Dec-16-25 07:30AM	REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata (PR Newswire) -7.77%
06:24AM	Nektar sees silver lining as autoimmune drug narrowly misses in alopecia study (BioPharma Dive)
Dec-15-25 06:00PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 (PR Newswire)
Dec-08-25 12:00PM	Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy (Zacks)
Dec-05-25 06:00PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-01-25 09:55AM	Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade (Zacks) -6.29%
Nov-26-25 09:43AM	Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls (The Fly) +8.85%
Nov-23-25 07:02AM	Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now? (Insider Monkey)
Nov-20-25 06:57AM	Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. (Motley Fool) -8.68%
Nov-13-25 09:55AM	Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect? (Zacks) -6.45%
05:45PM	Loading…
Nov-08-25 05:45PM	New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Nov-07-25 10:11AM	Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
12:07AM	Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Nov-06-25 05:55PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:06PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 10:00AM	Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) -7.72%
Oct-30-25 06:00PM	Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (PR Newswire) +5.32%
10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 06:00PM	Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
09:55AM	Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High? (Zacks)
Oct-26-25 06:06AM	Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation (Insider Monkey)
Oct-22-25 08:00AM	Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Oct-13-25 08:37AM	This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street (Motley Fool) +5.63%
Oct-05-25 08:41AM	Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September (Motley Fool)
Sep-25-25 05:22AM	Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock? (Zacks) -7.81%
Sep-21-25 06:43PM	These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? (Motley Fool)
Sep-18-25 05:34PM	Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today (Motley Fool) +15.06% -6.16%
12:23PM	EADV 25: Nektar presents data from AD candidate that sent stocks flying (Clinical Trials Arena)
08:45AM	Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 (PR Newswire)
Sep-09-25 07:00AM	Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 (PR Newswire) +9.56%
Sep-08-25 11:27AM	NKTR Shares Surge 38.2% in a Week: Here's What You Should Know (Zacks) +10.33%
Sep-05-25 01:32PM	Why Nektar Therapeutics Rippled Higher This Week (Motley Fool) +11.67%
Sep-03-25 07:00PM	Nektar Therapeutics to Participate in Two Investor Conferences in September (PR Newswire) +26.02%
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-08-25 06:15PM	Why Nektar Therapeutics Stock Popped 6% on Friday (Motley Fool) +6.02%
11:45AM	Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y (Zacks)
Aug-07-25 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:33PM	Nektar: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-05-25 06:10PM	Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-04-25 11:55AM	Nektar Gears Up to Report Q2 Earnings: What's in the Cards? (Zacks)
10:00AM	Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-31-25 06:00PM	Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets (PR Newswire) +5.90%
Jul-29-25 09:00AM	Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata (PR Newswire)
01:31AM	Nektar Therapeutics (NKTR) Announced Positive results for Rezpegaldesleukin (Insider Monkey)
Jul-21-25 11:02AM	3 Bullish Biotech Stocks With Explosive Growth Trends (MarketBeat)
Jul-06-25 04:01AM	Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin (Insider Monkey)
Jul-03-25 07:00PM	Why Nektar Therapeutics Stock Dived by 3% Today (Motley Fool) -5.21%
Jul-02-25 04:15PM	Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jul-01-25 07:17AM	Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire)
Jun-30-25 04:02PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
02:21PM	Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains (MarketBeat)
Jun-28-25 08:15AM	Nektar Jumps 157% on Drug Trial Data-Can It Go Even Higher? (MarketBeat)
Jun-25-25 06:45PM	Why Nektar Therapeutics Stock Was Red-Hot Today (Motley Fool) +19.10%
12:20PM	Wainwright sets over $100 target for Nektar on paradigm-shifting data (TipRanks)
11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 04:23PM	Nektar Therapeutics Launches After Unearthing 'A New Biology' In Eczema Treatment (Investor's Business Daily) +156.29%
10:54AM	Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results (Investopedia)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
09:07AM	Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam (Investor's Business Daily)
07:30AM	REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Jun-23-25 04:30PM	Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 (PR Newswire) +12.10%
May-13-25 05:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference (PR Newswire)
May-09-25 02:29PM	Q1 2025 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
09:08AM	Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down (Zacks)
03:46AM	Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... (GuruFocus.com)
May-08-25 06:25PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:19PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2025 Financial Results (PR Newswire)
May-07-25 05:20PM	Nektar Therapeutics Q1 2025 Earnings Preview (Seeking Alpha) -5.67%
May-01-25 06:00PM	Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-11-25 02:29PM	Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 (GuruFocus.com) +23.76%
11:30AM	Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? (Zacks)
Mar-22-25 06:57PM	Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil (Insider Monkey)
Mar-20-25 06:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
Mar-14-25 07:33AM	Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised) (Zacks) +9.98%
Mar-13-25 12:06PM	Q4 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zalevsky Jonathan	Chief R&D Officer	Jan 20 '26	Sale	35.67	3,867	137,936	21,354	Jan 22 07:31 PM
Zalevsky Jonathan	Officer	Jan 20 '26	Proposed Sale	35.67	3,867	137,946		Jan 20 04:21 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 25 '25	Sale	54.28	1,157	62,802	18,971	Nov 25 08:30 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 25 '25	Sale	54.28	630	34,196	21,585	Nov 25 08:29 PM
ROBIN HOWARD W	President & CEO	Nov 25 '25	Sale	54.28	2,207	119,796	54,245	Nov 25 08:28 PM
ROBIN HOWARD W	Officer	Nov 25 '25	Proposed Sale	58.82	2,207	129,812		Nov 25 03:35 PM
Wilson Mark Andrew	Officer	Nov 25 '25	Proposed Sale	58.82	630	37,056		Nov 25 03:32 PM
Zalevsky Jonathan	Officer	Nov 25 '25	Proposed Sale	58.82	1,157	68,053		Nov 25 03:28 PM
ROBIN HOWARD W	President & CEO	Sep 09 '25	Sale	46.69	6,666	311,214	49,342	Sep 11 09:01 PM
ROBIN HOWARD W	Officer	Sep 09 '25	Proposed Sale	46.69	6,666	311,205		Sep 09 04:57 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 04 '25	Sale	33.52	1,721	57,693	17,462	Sep 08 08:32 PM
ROBIN HOWARD W	President & CEO	Sep 05 '25	Sale	38.53	6,666	256,851	56,008	Sep 08 08:31 PM
ROBIN HOWARD W	President & CEO	Sep 04 '25	Sale	33.70	5,166	174,108	62,674	Sep 08 08:31 PM
ROBIN HOWARD W	Officer	Sep 05 '25	Proposed Sale	38.53	6,666	256,838		Sep 05 04:37 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 02 '25	Sale	30.10	485	14,598	19,183	Sep 04 09:02 PM
ROBIN HOWARD W	President & CEO	Sep 02 '25	Sale	30.16	1,500	45,240	67,840	Sep 04 09:01 PM
ROBIN HOWARD W	Officer	Sep 04 '25	Proposed Sale	33.70	5,166	174,119		Sep 04 05:06 PM
Zalevsky Jonathan	Officer	Sep 04 '25	Proposed Sale	33.52	1,721	57,688		Sep 04 04:19 PM
Zalevsky Jonathan	Officer	Sep 02 '25	Proposed Sale	30.10	485	14,600		Sep 02 04:45 PM
ROBIN HOWARD W	Officer	Sep 02 '25	Proposed Sale	30.16	1,500	45,244		Sep 02 04:42 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 19 '25	Sale	26.59	725	19,278	19,668	Aug 21 09:05 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 19 '25	Sale	26.59	676	17,975	20,312	Aug 21 09:04 PM
ROBIN HOWARD W	President & CEO	Aug 19 '25	Sale	26.59	1,573	41,826	69,340	Aug 21 09:03 PM
ROBIN HOWARD W	Officer	Aug 19 '25	Proposed Sale	26.59	1,573	41,826		Aug 19 03:24 PM
Wilson Mark Andrew	Officer	Aug 19 '25	Proposed Sale	26.59	676	17,975		Aug 19 03:24 PM
Zalevsky Jonathan	Officer	Aug 19 '25	Proposed Sale	26.59	725	19,278		Aug 19 03:20 PM
Zalevsky Jonathan	Chief R&D Officer	May 19 '25	Sale	0.67	10,712	7,177	305,892	May 21 08:08 PM
Wilson Mark Andrew	Chief Legal Officer	May 19 '25	Sale	0.67	9,996	6,697	314,296	May 21 08:07 PM
ROBIN HOWARD W	President & CEO	May 19 '25	Sale	0.67	23,208	15,549	1,063,693	May 21 08:07 PM
Zalevsky Jonathan	Officer	May 19 '25	Proposed Sale	0.67	10,712	7,191		May 19 03:49 PM
Wilson Mark Andrew	Officer	May 19 '25	Proposed Sale	0.67	9,996	6,710		May 19 03:44 PM
ROBIN HOWARD W	Officer	May 19 '25	Proposed Sale	0.67	23,208	15,580		May 19 03:40 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 19 '25	Sale	1.01	10,300	10,403	316,604	Feb 21 06:07 PM
Wilson Mark Andrew	Chief Legal Officer	Feb 19 '25	Sale	1.01	11,040	11,150	324,292	Feb 21 06:06 PM
ROBIN HOWARD W	President & CEO	Feb 19 '25	Sale	1.01	23,774	24,012	1,086,901	Feb 21 06:04 PM
Wilson Mark Andrew	Officer	Feb 19 '25	Proposed Sale	1.01	11,040	11,137		Feb 19 03:27 PM
ROBIN HOWARD W	Officer	Feb 19 '25	Proposed Sale	1.01	23,774	23,983		Feb 19 03:21 PM
Zalevsky Jonathan	Officer	Feb 19 '25	Proposed Sale	1.01	10,300	10,391		Feb 19 03:18 PM

Open in Screener

RZLT

Rezolute Inc

Feb 13 • 04:00PM ET

3.84

+0.21 5.79 %

Healthcare • Biotechnology • USA • NASD

Peers: ASND KRYS SWTX LGND RAPT SVRA IMTX UBX RKDA

| Held by: XBI IWM VTI IWO VXF SCHA VTWO IWC BBC VHT

Index	RUT	P/E	-	EPS (ttm)	-0.92	Insider Own	20.39%	Shs Outstand	95.55M	Perf Week	23.08%
Market Cap	367.48M	Forward P/E	-	EPS next Y	-0.73	Insider Trans	0.63%	Shs Float	76.18M	Perf Month	41.18%
Enterprise Value	235.82M	PEG	-	EPS next Q	-0.17	Inst Own	102.65%	Short Float	24.91%	Perf Quarter	-61.60%
Income	-84.23M	P/S	-	EPS this Y	24.80%	Inst Trans	-6.62%	Short Ratio	2.71	Perf Half Y	-40.56%
Sales	0.00M	P/B	2.87	EPS next Y	0.68%	ROA	-67.21%	Short Interest	18.98M	Perf YTD	62.71%
Book/sh	1.34	P/C	2.76	EPS next 5Y	18.44%	ROE	-74.02%	52W High	11.46 -66.48%	Perf Year	-20.17%
Cash/sh	1.39	P/FCF	-	EPS past 3/5Y	24.95% 22.65%	ROIC	-65.49%	52W Low	1.07 258.88%	Perf 3Y	42.75%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.53% 9.40%	Perf 5Y	-68.41%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	24.34%	Oper. Margin	-	ATR (14)	0.36	Perf 10Y	-93.02%
Dividend Ex-Date	-	Quick Ratio	14.18	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	59.72	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	14.18	EPS Q/Q	2.36%	SMA20	18.78%	Beta	0.49	Target Price	4.75
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	7.59%	Rel Volume	0.90	Prev Close	3.63
Employees	71	LT Debt/Eq	0.00	Earnings	Feb 12 AMC	SMA200	-35.27%	Avg Volume	7.01M	Price	3.84
IPO	May 08, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.77% -	Trades		Volume	6,327,164	Change	5.79%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-25	Downgrade	Wedbush	Outperform → Neutral	$1
Dec-11-25	Downgrade	Craig Hallum	Buy → Hold	$2
Dec-11-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-05-24	Initiated	Wedbush	Outperform	$12
Aug-27-24	Initiated	Guggenheim	Buy	$11
Jul-17-24	Initiated	BTIG Research	Buy	$13
Jun-04-24	Initiated	Craig Hallum	Buy	$14
Apr-09-24	Initiated	Maxim Group	Buy	$8
Aug-02-22	Resumed	Canaccord Genuity	Buy	$17
Jun-15-22	Initiated	Cantor Fitzgerald	Overweight	$9
Sep-08-21	Initiated	ROTH Capital	Buy	$21
May-27-21	Initiated	Oppenheimer	Outperform	$25
May-25-21	Initiated	H.C. Wainwright	Buy	$21

Show Previous Ratings

Feb-12-26 04:05PM	Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update (GlobeNewswire) +7.72% +5.79%
Feb-04-26 07:00AM	Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -7.62%
Jan-14-26 11:58AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) +9.68%
Jan-07-26 07:00AM	Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism (GlobeNewswire) +23.04%
Dec-31-25 11:12AM	Rezolute's Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing (Insider Monkey) +7.76%
04:39PM	Loading…
Dec-30-25 04:39PM	Insiders Made Their Bets in 2025-These Were the Top 5 Stocks They Bought (MarketBeat) -9.88%
Dec-23-25 09:30AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) +18.05%
Dec-18-25 01:49PM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire) -7.96%
Dec-17-25 09:47AM	RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know (Zacks)
Dec-15-25 01:06PM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating RZLT Investors with Losses Encouraged to Contact the Firm (PR Newswire) -9.44%
09:35AM	Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround (Zacks)
Dec-12-25 12:28PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily) +28.57%
11:52AM	Rezolute stock crashes after sole pipeline candidate fails Phase III (Clinical Trials Arena)
08:30AM	Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating (PR Newswire)
05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
07:59PM	Loading…
Dec-11-25 07:59PM	Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure (Business Wire) -87.20%
06:41PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily)
07:00AM	Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism (GlobeNewswire)
Dec-01-25 09:55AM	How Much Upside is Left in Rezolute (RZLT)? Wall Street Analysts Think 56.58% (Zacks) -5.66%
Nov-12-25 12:00PM	All You Need to Know About Rezolute (RZLT) Rating Upgrade to Buy (Zacks)
09:55AM	Can Rezolute (RZLT) Climb 49.4% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-10-25 05:30PM	Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.48%
Nov-06-25 04:05PM	Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update (GlobeNewswire) +12.08%
Nov-05-25 07:30AM	Rezolute to Host Virtual Investor Event on Ersodetug Development Program (GlobeNewswire) +5.06%
Oct-29-25 11:57AM	Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy (Insider Monkey)
Oct-15-25 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.89%
Oct-09-25 04:05PM	Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.34%
Sep-17-25 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire) +6.36%
07:05AM	Rezolute Stock: FDA Fast Track Fuels 2025 Breakout (MarketBeat)
Sep-02-25 07:30AM	Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism (GlobeNewswire)
07:30AM	Loading…
Aug-27-25 07:30AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 07:30AM	Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer (GlobeNewswire)
Aug-13-25 07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Jul-22-25 07:30AM	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-09-25 07:30AM	Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) (GlobeNewswire) +6.24%
May-28-25 08:00AM	Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism (GlobeNewswire)
May-20-25 12:08PM	Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential (Insider Monkey)
May-13-25 04:05PM	Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-05-25 08:00AM	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
May-01-25 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.32%
03:57AM	Rezolute: RZ402 Could Be A Surprise Candidate In The Making (Seeking Alpha)
Apr-25-25 04:30PM	Rezolute, Inc. Announces Closing of Underwritten Offering (GlobeNewswire)
Apr-23-25 08:05AM	Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) +27.65%
08:00AM	Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism ( HI ) (GlobeNewswire)
Apr-11-25 12:00PM	Rezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-26-25 07:30AM	Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors (GlobeNewswire) -5.54%
Feb-12-25 04:05PM	Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-04-25 08:00AM	Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Jan-31-25 08:00AM	Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-07-25 08:00AM	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Dec-05-24 08:00AM	Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-24 08:00AM	FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
Nov-07-24 04:05PM	Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-19-24 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.39%
Sep-09-24 07:30AM	FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study (GlobeNewswire) +22.07%
Aug-27-24 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-05-24 07:30AM	Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
Jul-31-24 08:00AM	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-27-24 08:00AM	Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire)
Jun-24-24 08:00AM	Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds (GlobeNewswire) +7.85%
Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -23.45%
Jun-13-24 11:30PM	Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.84%
04:01PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-30-24 08:00AM	Rezolute to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -6.33%
06:27AM	Rezolute's oral Eylea rival hits phase 2 goal, sending stock up and sparking partnership talk (FierceBiotech.com)
May-21-24 04:05PM	Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) (GlobeNewswire) +6.76%
May-15-24 10:54PM	RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024 (InvestorPlace)
04:05PM	Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-23-24 08:00AM	Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting (GlobeNewswire) -19.21%
Mar-20-24 02:33PM	Hedge Fund and Insider Trading News: Ken Griffin, Nelson Peltz, Palliser Capital, Elliott Management, Three Arrows Capital, Rezolute, Inc. (RZLT), Tesla Inc (TSLA), and More (Insider Monkey)
Mar-06-24 07:30AM	Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) (GlobeNewswire)
Feb-13-24 04:05PM	Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update (GlobeNewswire) +13.76%
Jan-24-24 08:00AM	Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer (GlobeNewswire) +6.37%
Jan-23-24 08:00AM	Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Dec-14-23 08:00AM	Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism (GlobeNewswire)
Dec-13-23 08:00AM	Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema ( DME ) (GlobeNewswire) +8.37%
Nov-24-23 11:14AM	Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an 'XBI-MAS' (Newsfile)
Nov-17-23 08:00AM	Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day (GlobeNewswire)
Nov-13-23 04:05PM	Rezolute Reports First Quarter Fiscal 2024 Results (GlobeNewswire) +12.22% -7.39%
Oct-17-23 08:00AM	Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +6.52%
Oct-11-23 08:00AM	Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism (GlobeNewswire) -6.00%
Sep-14-23 04:05PM	Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Sep-06-23 07:00AM	Rezolute to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Jun-27-23 04:05PM	Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism (GlobeNewswire)
Jun-01-23 12:45PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease (Newsfile) -7.51%
May-11-23 04:05PM	Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Mar-23-23 04:50PM	Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema (GlobeNewswire) -5.34%
Mar-08-23 07:00AM	Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert (GlobeNewswire) +7.44%
Feb-10-23 04:05PM	Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Dec-15-22 07:00AM	Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema (GlobeNewswire)
Nov-09-22 04:05PM	Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Nov-01-22 07:00AM	Rezolute to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-20-22 07:00AM	Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting (GlobeNewswire)
Sep-15-22 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress (GlobeNewswire)
Sep-07-22 07:00AM	Rezolute Announces Presentation at the 60th Annual ESPE Meeting (GlobeNewswire)
Aug-15-22 08:36AM	Here's What Rezolute, Inc.'s (NASDAQ:RZLT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jun-01-22 07:00AM	Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer (GlobeNewswire)
May-12-22 04:05PM	Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire) +6.15%

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The firm's antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hogenhuis Wladimir	Director	Dec 16 '25	Buy	1.69	5,650	9,548	119,675	Dec 17 04:14 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Dec 16 '25	Buy	1.70	28,000	47,600	308,352	Dec 17 04:13 PM
Evans Daron	CFO	Dec 15 '25	Buy	1.77	40,000	70,640	415,900	Dec 15 07:35 PM
Evans Daron	CFO	Dec 15 '25	Buy	1.79	5,000	8,938	7,000	Dec 15 07:35 PM
Elam Nevan C	CEO	Dec 15 '25	Buy	1.59	32,000	50,880	641,119	Dec 15 07:35 PM
Karnawat Sunil Ratilal	Chief Commercial Officer	Dec 15 '25	Buy	1.62	12,100	19,599	71,542	Dec 15 07:34 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jun 25 '25	Buy	4.38	2,500	10,939	15,500	Jun 26 09:07 AM
Evans Daron	CFO	Jun 24 '25	Buy	4.05	5,000	20,250	268,900	Jun 24 12:41 PM
Kim Young-Jin	Director	Jun 13 '25	Buy	3.25	1,230,769	3,999,999	8,423,386	Jun 23 09:38 AM
KREHER NERISSA	Director	Jun 13 '25	Buy	3.25	3,076	9,997	37,576	Jun 23 09:12 AM
Hogenhuis Wladimir	Director	Mar 31 '25	Buy	2.92	6,758	19,733	84,025	Apr 01 03:52 PM
Elam Nevan C	CEO	Mar 27 '25	Buy	2.85	12,302	34,999	224,119	Mar 31 09:18 AM
Evans Daron	CFO	Mar 26 '25	Buy	2.89	10,000	28,900	237,900	Mar 28 08:40 AM
Evans Daron	CFO	Mar 26 '25	Buy	2.88	10,000	28,800	23,000	Mar 28 08:40 AM
Hogenhuis Wladimir	Director	Feb 18 '25	Buy	4.70	10,000	47,000	77,267	Feb 20 07:59 PM
Evans Daron	CFO	Dec 09 '25	Buy	5.04	10,549	53,167	131,900	Dec 10 09:11 AM

NKTR

Nektar Therapeutics

RZLT

Rezolute Inc

Upgrade your FINVIZ experience